Elias Jabbour, MD, on 2024 MDS Highlights
By Elias Jabbour, MD - Last Updated: June 27, 2024During the European Hematology Association (EHA) 2024 Congress , Dr. Jabbour spoke with Blood Cancers Today on his top highlights in myelodysplastic syndromes (MDS) so far.
Advertisement
Advertisement
Related Posts
Samir Parekh, MD, Appointed Director of the Center of Excellence for Multiple Myeloma at Mount Sinai
Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma.
GPC-100 is a a small molecule CXCR4 inhibitor that showed promising preclinical activity in combination with cytarabine.
Douglas Graham, MD, PhD, a hematologist-oncologist specializing in pediatric leukemia, was recognized in Atlanta Magazine.
Tycel Phillips, MD, discussed his presentation on BTK inhibitors from the International Ultmann Chicago Lymphoma Symposium.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.